Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Artigo em Inglês | MEDLINE | ID: mdl-26261140

RESUMO

Fungal infections are amongst the most commonly encountered diseases affecting the skin. Treatment approaches include both topical and oral antifungal agents. The topical route is generally preferred due to the possible side effects of oral medication. Advances in the field of formulation may soon render outdated conventional products such as creams, ointments and gels. Several carrier systems loaded with antifungal drugs have demonstrated promising results in the treatment of skin fungal infections. Examples of these newer carriers include micelles, lipidic systems such as solid lipid nanoparticles and nanostructured lipid carriers, microemulsions and vesicular systems such as liposomes, niosomes, transfersomes, ethosomes, and penetration enhancer vesicles.


Assuntos
Antifúngicos/administração & dosagem , Dermatomicoses/tratamento farmacológico , Portadores de Fármacos/administração & dosagem , Administração Tópica , Animais , Antifúngicos/metabolismo , Química Farmacêutica , Dermatomicoses/metabolismo , Portadores de Fármacos/metabolismo , Humanos
2.
Food Microbiol ; 46: 114-120, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25475274

RESUMO

Biocontrol using autochthonous Debaryomyces hansenii isolates is a potentially suitable strategy for inhibiting toxigenic moulds in dry-cured meat products. The antifungal activity of 280 D. hansenii isolated from dry-cured meat products as well as the mode of action of the most active isolates against toxigenic penicillia were evaluated in this work. A 13.9% of the D. hansenii isolates showed inhibitory activity in a radial inhibition assay. The effects on penicillia growth of both the cell-free culture filtrate and volatile compounds from active yeast isolates were analysed. Penicillia growth inhibition by D. hansenii was probably based on additive or synergistic effects of several inhibiting factors such as competition for nutrient and space, and production of soluble or volatile compounds. When four D. hansenii isolates were tested on dry-fermented sausage, two of them produced a significantly growth reduction of the ochratoxigenic Penicillium verrucosum, keeping its counts under the level considered as hazardous for the mycotoxin presence. Therefore, the use of these two D. hansenii isolates during the processing of dry-fermented meat product could be a promising tool to control toxigenic moulds in the meat industry.


Assuntos
Antifúngicos/farmacologia , Debaryomyces/química , Debaryomyces/metabolismo , Produtos da Carne/microbiologia , Penicillium/crescimento & desenvolvimento , Animais , Antifúngicos/química , Antifúngicos/metabolismo , Debaryomyces/isolamento & purificação , Fermentação , Penicillium/efeitos dos fármacos , Suínos
3.
J Basic Microbiol ; 54(5): 448-56, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-23553741

RESUMO

In recent years, Bacillus species have received considerable attention for the biological control of many fungal diseases. In this study, Bacillus amyloliquefaciens Q-426 was tested for its potential use against a variety of plant pathogens. Our screen for genes involved in the biosynthesis of antifungal agents revealed that the fen and bmy gene clusters are present in the Q-426 genome. Lipopeptides such as bacillomycin D, fengycin A, and fengycin B were purified from the bacterial culture broth and subsequently identified by ESI-mass spectrometry. The minimal inhibitory concentration of fengycin A against Fusarium oxysporum f. sp. spinaciae W.C. Snyder & H.N. Hansen O-27 was determined to be 31.25 µg ml(-1) . However, exposure of fungal cells to 50 µg ml(-1) of fengycin A did not allow permeation of fluorescein diacetate into the cytoplasm through the cell membrane. Moreover, leakage of intracellular inorganic cations, nucleic acid and protein were also not detected, indicating that the fungal cell membrane is not the primary target of action for fengycin A. Profound morphological changes were observed in the F. oxysporum strain and spore germination was completely inhibited, suggesting that 50 µg ml(-1) of fengycin A acts, at least, as a fungistatic agent.


Assuntos
Antibiose , Antifúngicos/farmacologia , Bacillus/fisiologia , Fusarium/crescimento & desenvolvimento , Lipopeptídeos/farmacologia , Peptídeos/farmacologia , Controle Biológico de Vetores/métodos , Antifúngicos/isolamento & purificação , Antifúngicos/metabolismo , Peptídeos Catiônicos Antimicrobianos , Bacillus/genética , Bacillus/crescimento & desenvolvimento , Bacillus/metabolismo , Fusarium/efeitos dos fármacos , Lipopeptídeos/isolamento & purificação , Lipopeptídeos/metabolismo , Testes de Sensibilidade Microbiana , Família Multigênica , Peptídeos/isolamento & purificação , Peptídeos/metabolismo
4.
Antimicrob Agents Chemother ; 56(1): 391-402, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22037849

RESUMO

CYP164 family P450 enzymes are found in only a subset of mycobacteria and include CYP164A1, which is the sole P450 found in Mycobacterium leprae, the causative agent of leprosy. This has previously led to interest in this enzyme as a potential drug target. Here we describe the first crystal structure of a CYP164 enzyme, CYP164A2 from Mycobacterium smegmatis. CYP164A2 has a distinctive, enlarged hydrophobic active site that extends above the porphyrin ring toward the access channels. Unusually, we find that CYP164A2 can simultaneously bind two econazole molecules in different regions of the enlarged active site and is accompanied by the rearrangement and ordering of the BC loop. The primary location is through a classic interaction of the azole group with the porphyrin iron. The second econazole molecule is bound to a unique site and is linked to a tetracoordinated metal ion complexed to one of the heme carboxylates and to the side chains of His 105 and His 364. All of these features are preserved in the closely homologous M. leprae CYP164A1. The computational docking of azole compounds to a homology model of CYP164A1 suggests that these compounds will form effective inhibitors and is supported by the correlation of parallel docking with experimental binding studies of CYP164A2. The binding of econazole to CYP164A2 occurs primarily through the high-spin "open" conformation of the enzyme (K(d) [dissociation constant] of 0.1 µM), with binding to the low-spin "closed" form being significantly hindered (K(d) of 338 µM). These studies support previous suggestions that azole derivatives may provide an effective strategy to improve the treatment of leprosy.


Assuntos
Antifúngicos/metabolismo , Proteínas de Bactérias/química , Sistema Enzimático do Citocromo P-450/química , Econazol/metabolismo , Hanseníase/tratamento farmacológico , Mycobacterium leprae , Antifúngicos/farmacologia , Proteínas de Bactérias/antagonistas & inibidores , Proteínas de Bactérias/metabolismo , Sítios de Ligação , Domínio Catalítico , Sequência Conservada , Cristalografia por Raios X , Inibidores das Enzimas do Citocromo P-450 , Sistema Enzimático do Citocromo P-450/metabolismo , Econazol/farmacologia , Heme/metabolismo , Histidina/metabolismo , Humanos , Ferro/metabolismo , Cinética , Hanseníase/microbiologia , Modelos Moleculares , Infecções por Mycobacterium não Tuberculosas/microbiologia , Mycobacterium leprae/efeitos dos fármacos , Mycobacterium leprae/enzimologia , Mycobacterium smegmatis/química , Mycobacterium smegmatis/enzimologia , Porfirinas/metabolismo , Ligação Proteica , Estrutura Secundária de Proteína
5.
PLoS One ; 6(2): e16869, 2011 Feb 08.
Artigo em Inglês | MEDLINE | ID: mdl-21346818

RESUMO

BACKGROUND: The unique cell wall of bacteria of the suborder Corynebacterineae is essential for the growth and survival of significant human pathogens including Mycobacterium tuberculosis and Mycobacterium leprae. Drug resistance in mycobacteria is an increasingly common development, making identification of new antimicrobials a priority. Recent studies have revealed potent anti-mycobacterial compounds, the benzothiazinones and dinitrobenzamides, active against DprE1, a subunit of decaprenylphosphoribose 2' epimerase which forms decaprenylphosphoryl arabinose, the arabinose donor for mycobacterial cell wall biosynthesis. Despite the exploitation of Mycobacterium smegmatis in the identification of DprE1 as the target of these new antimicrobials and its use in the exploration of mechanisms of resistance, the essentiality of DprE1 in this species has never been examined. Indeed, direct experimental evidence of the essentiality of DprE1 has not been obtained in any species of mycobacterium. METHODOLOGY/PRINCIPAL FINDINGS: In this study we constructed a conditional gene knockout strain targeting the ortholog of dprE1 in M. smegmatis, MSMEG_6382. Disruption of the chromosomal copy of MSMEG_6382 was only possible in the presence of a plasmid-encoded copy of MSMEG_6382. Curing of this "rescue" plasmid from the bacterial population resulted in a cessation of growth, demonstrating gene essentiality. CONCLUSIONS/SIGNIFICANCE: This study provides the first direct experimental evidence for the essentiality of DprE1 in mycobacteria. The essentiality of DprE1 in M. smegmatis, combined with its conservation in all sequenced mycobacterial genomes, suggests that decaprenylphosphoryl arabinose synthesis is essential in all mycobacteria. Our findings indicate a lack of redundancy in decaprenylphosphoryl arabinose synthesis in M. smegmatis, despite the relatively large coding capacity of this species, and suggest that no alternative arabinose donors for cell wall biosynthesis exist. Overall, this study further validates DprE1 as a promising target for new anti-mycobacterial drugs.


Assuntos
Antifúngicos/metabolismo , Benzamidas/metabolismo , Mycobacterium smegmatis/enzimologia , Racemases e Epimerases/metabolismo , Tiazinas/metabolismo , Sequência de Aminoácidos , Antifúngicos/farmacologia , Benzamidas/farmacologia , Biocatálise , Parede Celular/enzimologia , Parede Celular/metabolismo , Descoberta de Drogas , Técnicas de Inativação de Genes , Dados de Sequência Molecular , Mycobacterium smegmatis/citologia , Mycobacterium smegmatis/efeitos dos fármacos , Mycobacterium smegmatis/crescimento & desenvolvimento , Ligação Proteica , Racemases e Epimerases/química , Racemases e Epimerases/deficiência , Racemases e Epimerases/genética , Homologia de Sequência de Aminoácidos , Tiazinas/farmacologia
6.
Appl Microbiol Biotechnol ; 86(3): 965-72, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20039034

RESUMO

The nature of the toxic compounds produced by Saccharomyces cerevisiae CCMI 885 that induce the early death of Hanseniaspora guilliermondii during mixed fermentations, as well as their ability to inhibit the growth of other non-Saccharomyces wine-related strains, was investigated. The killing effect of mixed supernatants towards H. guilliermondii was inactivated by protease treatments, thus revealing the proteinaceous nature of the toxic compounds. Analysis of the protein pattern of mixed supernatants on Tricine SDS-PAGE showed that this S. cerevisiae strain secretes peptides (<10 kDa), which were detected only when death of H. guilliermondii was already established. Death-inducing supernatants were ultrafiltrated by 10 and 2 kDa membranes, respectively, and the inhibitory effect of those permeates were tested in H. guilliermondii cultures. Results indicated that the (2-10) kDa protein fraction of those supernatants seemed to contain antimicrobial peptides active against H. guilliermondii. Thus, the (2-10) kDa protein fraction was concentrated and its inhibitory effect tested against strains of Kluyveromyces marxianus, Kluyveromyces thermotolerans, Torulaspora delbrueckii and H. guilliermondii. Under the growth conditions used for these tests, the (2-10) kDa protein fraction of S. cerevisiae CCMI 885 supernatants exhibited a fungistatic effect against all the strains and a fungicidal effect against K. marxianus.


Assuntos
Antifúngicos/metabolismo , Antifúngicos/farmacologia , Proteínas Fúngicas/metabolismo , Proteínas Fúngicas/farmacologia , Hanseniaspora/efeitos dos fármacos , Saccharomyces cerevisiae/metabolismo , Antifúngicos/química , Antifúngicos/isolamento & purificação , Eletroforese em Gel de Poliacrilamida , Proteínas Fúngicas/química , Proteínas Fúngicas/isolamento & purificação , Kluyveromyces/efeitos dos fármacos , Viabilidade Microbiana/efeitos dos fármacos , Peso Molecular , Peptídeo Hidrolases/metabolismo , Proteoma/análise , Torulaspora/efeitos dos fármacos , Vinho/microbiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA